Bayer acquires rights to Micromet's BiTE antibody

Published: 2-Dec-2009
Ingredients Research & Development Pharmaceutical

Bayer Schering Pharma has exercised its option to buy the rights to an antibody for the treatment of solid tumours from US biotechnology company Micromet.


Bayer Schering Pharma has exercised its option to buy the rights to an antibody for the treatment of solid tumours from US biotechnology company Micromet.

Under the terms of the agreement signed in January 2009, Bayer had an option to licence a specific BiTE antibody against an undisclosed solid tumour target through the completion of Phase I clinical trials, at which point the German company will assume full control of further development and commercialisation of the antibody.

Taking up the option has triggered a Euro 5m to Micromet in January 2010. Micromet could receive milestone payments of up to €285m plus double-digit royalties. The company will also be reimbursed for its r&d expenses.

BiTE antibodies are designed to direct the body's cell-destroying T cells against tumour cells, and represent a new approach to cancer therapy.

"BiTE antibodies represent a promising approach to cancer therapy," said Karl Ziegelbauer, head of therapeutic research oncology at Bayer Schering Pharma. "We are looking forward to developing a new treatment for patients with solid tumours and to advance novel therapeutic options in our oncology portfolio."

  • Companies:
  • Bayer
See more

You may also like

Research & Development

Recursion adds new chemical entity targeting fibrotic diseases to late discovery pipeline

Read more
Potential first-in-class molecule with novel target inlicensed from collaboration with Bayer

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
  3. Naobios and Sumagen sign exclusive partnership to develop HIV vaccine Naobios will manage process development and initiate launch of cGMP manufacturing for phase II clinical trials
  4. 4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
  5. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Research & Development

Recursion adds new chemical entity targeting fibrotic diseases to late discovery pipeline

Potential first-in-class molecule with novel target inlicensed from collaboration with Bayer
Ingredients

Therapeutic: asundexian for atrial fibrillation

In atrial fibrillation, the atria of the heart contract irregularly; as a result, they do not empty completely and prevent the correct flow of blood
Finance

Bayer strengthens cell and gene therapies with BlueRock acquisition

BlueRock Therapeutics is a privately-held biotech company headquartered in the US
Regulatory

Pistoia Alliance announces data management toolkit

Roche, AstraZeneca and Bayer supports FAIR Implementation project to improve data management and better AI and machine learning for the "Lab of the Future"
Design & Build

Bayer chooses Fluor and GE Healthcare for new cell culture technology centre

Company will invest US$150 million in new California facility expected to be ready for clinical production in late 2021
Finance

Leaps by Bayer invests in cancer vaccines

The partnership with US-based Khloris Biosciences will develop new anti-cancer vaccines based on human induced pluripotent stem cells
Drug Delivery

Pilloxa forms strategic partnership with Bayer AB

By gaining access to both Bayer’s Scandinavian and global network through this new collaboration, Pilloxa will get the opportunity to expand the market and introduce more people to its smart pillbox
Subscribe now